Sygnature Discovery has acquired Canadian CRO NuChem Sciences in a move that expands the U.K.-based preclinical contractor’s global footprint.
NuChem Sciences, which was founded in 2011, employs more than 300 people in Montreal and Quebec City. The CRO offers integrated and standalone discovery services across medicinal, synthetic, scale-up, process and computational chemistry as well as DMPK (drug metabolism and pharmacokinetics) in vitro biology and in vivo pharmacology.
Financial terms of the deal weren’t disclosed in an Aug. 2 press release.
“The addition of NuChem Sciences greatly enhances Sygnature Discovery’s offering, making us a highly differentiated and integrated drug discovery partner with unrivalled scale and range,” Simon Hirst, Sygnature’s CEO, said in the release.
The deal marks Sygnature’s third acquisition in the past 16 months. The company bought Peak Proteins in April 2022, followed by SB Drug Discovery in January. Deal prices for those acquisitions weren’t disclosed.